Department of Internal Medicine, Division of Gastroenterology and Hepatology, UC Davis Medical Center, UC Davis School of Medicine, 4150 V Street, Suite 3500, Sacramento, CA 95817, USA.
Institute for Regenerative Cures, UC Davis, 2921 Stockton Blvd, Sacramento, CA 95817, USA.
Biomolecules. 2021 Jan 11;11(1):82. doi: 10.3390/biom11010082.
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gut that can lead to severe gastrointestinal symptoms, malnutrition, and complications such as fistulas and cancer. Mesenchymal stem/stromal cells (MSCs) are being investigated as a novel therapy for IBD and have been demonstrated to be safe and effective for perianal fistulizing Crohn's disease (PFCD). This systematic review aims to present the most recent studies on the safety and efficacy of MSC therapy in IBD. A detailed search strategy of clinical trials on MSCs and IBD was performed on PubMed, with 32 studies selected for inclusion in this review. The newest studies on local MSC injection for PFCD continue to support long-term efficacy while maintaining a favorable safety profile. The evidence for systemic MSC infusion in luminal IBD remains mixed due to marked methodological heterogeneity and unclear safety profiles. Although further studies are needed to better establish the role of this novel treatment modality, MSCs are proving to be a very exciting addition to the limited therapies available for IBD.
炎症性肠病（IBD）是一种慢性肠道炎症性疾病，可导致严重的胃肠道症状、营养不良以及瘘管和癌症等并发症。间充质干细胞（MSCs）作为 IBD 的一种新疗法正在被研究，并且已经被证明对肛周瘘管性克罗恩病（PFCD）是安全有效的。本系统综述旨在介绍关于 MSC 治疗 IBD 的最新安全性和有效性研究。对 PubMed 上关于 MSCs 和 IBD 的临床试验进行了详细的检索策略，有 32 项研究被纳入本综述。局部 MSC 注射治疗 PFCD 的最新研究继续支持长期疗效，同时保持良好的安全性。由于方法学异质性显著且安全性不明确，系统 MSC 输注治疗腔内 IBD 的证据仍存在分歧。尽管需要进一步的研究来更好地确定这种新治疗方法的作用，但 MSCs 正在成为 IBD 现有有限治疗方法的一个非常令人兴奋的补充。
